AIkido Pharma EBITDA 2011-2026 | AIKI

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA AIkido Pharma

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-11.4 M	-21.7 M	-14.3 M	-9.44 M	-736 K	-2.7 M	-5.43 M	-2.45 M	-6.41 M	-45.7 M	-20.8 M	-15.1 M	-	-4.28 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-736 K	-45.7 M	-12.3 M

Quarterly EBITDA AIkido Pharma

2025-Q3	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-2.78 M	-	-	-	-3.83 M	-	-5.1 M	-2.3 M	-3.8 M	-	-1.78 M	-2.76 M	-2.32 M	-	-966 K	-1.79 M	-2.4 M	-	-902 K	-888 K	-713 K	-	-1.93 M	-1.24 M	-1.58 M	-	-958 K	-434 K	-968 K	-	-1.48 M	-1.62 M	-2.09 M	-	-1.96 M	-40.3 M	-4.12 M	-	-2.69 M	-9.14 M	-8.01 M	-	-9.31 M	-942 K	-895 K	-	-583 K	-635 K	-1.05 M	-	-736 K	-987 K	-1.09 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-434 K	-40.3 M	-3.34 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	-150 M	$ 2.08	-14.4 %	$ 214 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Altimmune ALT	-103 M	$ 4.2	-2.67 %	$ 298 M	USA
Apellis Pharmaceuticals APLS	57 M	$ 20.24	-3.44 %	$ 2.55 B	USA
Aptorum Group Limited APM	1.19 M	$ 0.8	1.87 %	$ 4.36 M	China
Aprea Therapeutics APRE	-15.5 M	$ 0.88	-3.72 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	-24.2 M	$ 7.2	-1.64 %	$ 1.99 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Aquestive Therapeutics AQST	-30.1 M	$ 4.1	2.37 %	$ 356 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Arcturus Therapeutics Holdings ARCT	-92.1 M	$ 8.35	1.46 %	$ 225 M	Israel
Ardelyx ARDX	-37.9 M	$ 6.37	-2.75 %	$ 1.54 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
argenx SE ARGX	-349 M	$ 756.71	-1.33 %	$ 25 B	Niderland
Armata Pharmaceuticals ARMP	-39.9 M	$ 10.91	1.58 %	$ 394 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 25.33	-6.1 %	$ 3.22 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Artelo Biosciences ARTL	-11.4 M	$ 1.15	-3.36 %	$ 2.32 M	USA
Arvinas ARVN	-116 M	$ 12.97	-2.3 %	$ 920 M	USA
Arrowhead Pharmaceuticals ARWR	121 M	$ 61.74	-2.42 %	$ 8.26 B	USA
Ascendis Pharma A/S ASND	-452 M	$ 231.56	-0.83 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.39	-1.63 %	$ 8.16 B	Australia
Actinium Pharmaceuticals ATNM	-41.9 M	$ 1.17	-0.85 %	$ 35.2 M	USA
Atossa Therapeutics ATOS	-31.4 M	$ 4.39	-0.9 %	$ 553 M	USA
Atara Biotherapeutics ATRA	-78.4 M	$ 5.01	-7.47 %	$ 37.5 M	USA
Aurinia Pharmaceuticals AUPH	52.7 M	$ 14.14	-0.21 %	$ 1.9 B	Canada
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Autolus Therapeutics plc AUTL	-234 M	$ 1.68	-1.75 %	$ 429 M	Britain
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Atea Pharmaceuticals AVIR	-193 M	$ 4.69	0.21 %	$ 395 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Anavex Life Sciences Corp. AVXL	-51.4 M	$ 4.54	2.44 %	$ 387 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Axon Enterprise AXON	107 M	$ 570.5	5.18 %	$ 43.2 B	USA
Axsome Therapeutics AXSM	-166 M	$ 162.28	-0.98 %	$ 8.07 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Aytu BioScience AYTU	-2.45 M	$ 2.56	-0.58 %	$ 16.1 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA